Q3 2025 Arcticzymes Technologies ASA Earnings Call Transcript
Key Points
- ArcticZymes Technologies ASA (LTS:0DRV) reported a 24% increase in revenue, reaching nearly NOK30 million, with a significant rise in profitability to NOK3.5 million.
- The company executed a European partnership deal with Brenntag, enhancing its distribution network and expanding its market reach.
- Molecular tools sales saw a 45% increase compared to Q3 last year, driven by the return of a key account and growth from other accounts.
- Biomanufacturing sales are up 23% year-to-date, with an expanding customer base and increased uptake among CDMO partners.
- The company is actively working on strategic initiatives, including expanding its enzyme portfolio and exploring inorganic growth opportunities, positioning itself for future growth.
- Despite overall revenue growth, total nine-month revenues are down 1.9% when including their largest customer, indicating dependency on key accounts.
- The US market experienced a 10% decline in sales compared to Q3 2024, attributed to the timing of customer projects.
- Currency fluctuations, particularly the strengthening of NOK against the USD, negatively impacted net finance by NOK0.4 million in Q3.
- Personnel expenses increased due to hiring in the commercial team and variable remuneration accruals, impacting overall expenses.
- The company faces challenges in scaling its operations to meet future demand, requiring new measures to increase capacity, especially in nucleases.
Good morning and welcome to ArcticZymes Q3 Financial presentation. My name is Michael Akoh. I'm the CEO of the company and I'm joined by Børge Sørvoll, the CFO, as well as Paul Blackburn, our CCO. Thank you for joining us this, morning.
Next, slide, please. I look at our agenda for today. I'm going to go through our highlights of Q3 and also share an overview of our 2026 strategy. Then Paul is going to go into detail with our sales, both for the biomanufacturing as well as the molecular tools segment. Then Børge is going to come on and go into detail with our financials. Then I'm going to share an outlook as well as open up for questions and answers.
Next slide please. We had a solid quarter where our team delivered profitable growth across both segments. Our revenue was up by 24% to almost NOK30 million, and we also had a significant increase in our profitability that ended at NOK3.5 million.
A significant event after the quarter entered was the execution of a European partnership deal with Brenntag. Paul
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
